Clinical trials: Neuroendocrine Carcinoma (Carcinoid)
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor
Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.
The primary objectives are to determine the recommended Phase 2 dose (RP2D) and optimal treatment regimen, characterize safety and tolerability, and evaluate preliminary efficacy of RYZ401 in subjects with NETs and other selected…
- Conditions
- GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors
- Trial name
- NCT07165132
- Testing
- RYZ401
- Where
- 15 sites in United States, Canada
- Volunteers
- 104 people
- Sponsor
- RayzeBio, Inc.
Neuroendocrine Tumor, Carcinoid Tumor
Pasireotide in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors
The purpose of this research study is to determine the safety of the combination of SOM230 and RAD001, as well as determine the highest dose of this combination that can be given to people safely.
- Conditions
- Neuroendocrine Tumor, Carcinoid Tumor, Pancreatic Neuroendocrine Tumor
- Trial name
- NCT00804336
- Testing
- SOM230, RAD001
- Where
- 3 sites in United States
- Volunteers
- 22 people
- Sponsor
- Dana-Farber Cancer Institute
Neuroendocrine Carcinoma
Safety and Efficacy of Atiprimod Treatment for Patients With Low to Intermediate Grade Neuroendocrine Carcinoma
This study will evaluate the safety and efficacy of atiprimod treatment in patients with low to intermediate grade neuroendocrine carcinoma who have metastatic or unresectable local-regional cancer and who have either symptoms…
- Trial name
- NCT00388063
- Testing
- Atiprimod
- Where
- 8 sites in United States
- Volunteers
- 55 people
- Sponsor
- Callisto Pharmaceuticals
Malignant Carcinoid Syndrome
Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
The aim of this study is to compare the efficacy and safety of lanreotide Autogel and Sandostatin LAR Depot, to see whether these two 28-day prolonged release formulations produce a similar clinical response in patients with…
- Trial name
- NCT00092287
- Testing
- lanreotide Autogel (somatostatin analogue), Sandostatin long acting release (LAR) Depot (somatostatin analogue)
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ipsen
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Combination Chemotherapy as First-Line Therapy in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors of the Duodenum or Pancreas That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as fluorouracil, leucovorin, and irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome
- Trial name
- NCT00416767
- Testing
- fluorouracil, irinotecan hydrochloride, leucovorin calcium
- Volunteers
- 20 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Pheochromocytoma, Neuroblastoma
123I-MIBG Scintigraphy in Patients Being Evaluated for Neuroendocrine Tumors
The study is designed to study the safety and effectiveness of 123I-MIBG as a diagnostic imaging agent in evaluating patients with known or suspected neuroendocrine tumors.
- Conditions
- Pheochromocytoma, Neuroblastoma, Paraganglioma, Medullary Thyroid Carcinoma
- Trial name
- NCT01373736
- Testing
- 123I-meta-iodobenzylguanidine
- Where
- Canada
- Sponsor
- Vancouver Coastal Health
Carcinoid Syndrome, Carcinoid
Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen
A Phase 3, randomized, double-blinded, placebo-controlled study to evaluate the efficacy and safety of paltusotine treatment vs placebo as well as the long-term safety of paltusotine in adults with carcinoid syndrome due to…
- Conditions
- Carcinoid Syndrome, Carcinoid, Carcinoid Tumor, Carcinoid Tumor of Ileum
- Trial name
- CAREFNDR (NCT07087054)
- Testing
- Paltusotine
- Where
- 72 sites in United States, Argentina and 12 more
- Volunteers
- 141 people
- Sponsor
- Crinetics Pharmaceuticals Inc.
Neuroendocrine Tumors
Capecitabine and Temozolomide for Neuroendocrine Cancers
This phase II study is designed to assess whether treatment with capecitabine/temozolomide (CAP/TEM) is safe and effective in treating subjects with progressive, differentiated, metastatic neuroendocrine tumors (NET).
- Trial name
- NCT00869050
- Testing
- Capecitabine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Columbia University
Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor
Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine Cancer
This phase II trial studies how well pazopanib hydrochloride works in treating patients with advanced neuroendocrine cancer. Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for…
- Conditions
- Gastrin-Producing Neuroendocrine Tumor, Lung Carcinoid Tumor, Metastatic Digestive System Neuroendocrine Tumor G1, Multiple Endocrine Neoplasia Type 1
- Trial name
- NCT00454363
- Testing
- Laboratory Biomarker Analysis, Pazopanib Hydrochloride, Pharmacological Study
- Where
- 3 sites in United States
- Volunteers
- 52 people
- Sponsor
- National Cancer Institute (NCI)